Compare The Vita Coco Company Inc (COCO) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs Stryker Corporation — how do they compare? The Vita Coco Company Inc trades at $64.43 (market cap $3.63B), while Stryker Corporation trades at $347.43 (market cap $132.64B). The key difference: Stryker Corporation is far larger — about 36.5× The Vita Coco Company Inc's market cap, and Stryker Corporation pays a 1.02% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | SYK | |
|---|---|---|
Market Cap | $3.63B | $132.64B |
Sector | Technology | Technology |
52-Week High | $84.02 | $394.34 |
52-Week Low | $32.37 | $282.58 |
Enterprise Value | $3.37B | $144.11B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Vita Coco Company (COCO) trades at $62.25, down 2.92% over 24 hours, with a bullish technical signal driven by oversold RSI readings and support near $62. Fundamentally, Q2 2026 earnings beat expectations with EPS of $0.82 versus $0.56 estimated, while revenue grew 28% year-over-year to $216 million. The company raised full-year 2026 guidance, reflecting strong demand and the Copra acquisition.
Outlook remains positive with 60% analyst buy ratings and an $80.67 consensus price target, implying ~30% upside. Key risks include margin pressure from rising costs and capacity constraints. Growth catalysts include international expansion and health-focused innovation in the beverage sector.
Stryker (SYK) trades at $339.03, up 0.47% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $3.69 versus $3.49 expected, and demonstrated robust 9% organic sales growth. Analyst consensus is strongly positive with a $379.44 price target and 74% buy ratings. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS robotic technology.
The outlook remains favorable given earnings momentum and product innovation, though risks include competitive pressures and potential cyber disruptions. Valuation multiples such as a P/E of 35.84 suggest premium pricing, requiring sustained growth to justify. Institutional ownership trends show mixed activity, with some funds increasing stakes recently.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
